Research Article
Available online at www.ijpras.com
ISSN 2277-3657
Volume 1, issue 4 (2012), 36-39
International Journal of Pharmaceutical Research & Allied Sciences

Study of Novel Pyrrole Derivatives

Tarunkumar M. Patel * A.M Patel
Department of Applied science Singhania University Pacheri bari, jhunjhunu (raj.) India
E-mail : tarunpatel16185@yahoo.in

Subject: Medicinal Chemistry

Abstract

A facile condensation of aromatic aldehydes with 4-(1H-naphtho[1,8-de] [1,2,3] triazin-1-ylsulfonyl)aniline [1] was give the corresponding 4-(1H-naphtho[1,8-de] [1,2,3]triazin-1-ylsulfonyl)-N-arylidene aniline [2a-e] in good yield. Cyclo condensation of compounds [2a-e] with maleic anhydride yields 1-(4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl) phenyl)-2-aryl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid [3a-e]. The structures of these compounds were established on the basis of analytical and spectral data. All the newly synthesized compounds were evaluated for their antibacterial and antifungal activities.

Keywords: *4-(1H-naphtho[1,8-de] [1,2,3] triazin-1-ylsulfonyl)aniline, pyrrole, antibacterial and antifungal activities* **.**

Introduction

Schiff's base and their heterocyclised products display diverse biological activities including antibacterial, antifungicidal, analgesic, anti-inflammatory properties [1-10]. These heterocyclic systems find wide use in medicine, agriculture and industry. One of the other compounds says, triazoles and their condensed products play a vital role in medicinal chemistry [11-13]. 2-pyrrole and its arylidene compounds give good pharmacological properties [14-20]. Hence, it was thought of interest to merge both of pyrrole and triazine moieties which may enhance the drug activity of compounds to some extent, or they might possess some of the above mentioned biological activities. From this point of view, the objective of the present work is to prepare new derivatives of triazine containing pyrrole moiety. Hence the current communication covers the study of 1-(4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)phenyl)-2-aryl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid. The synthetic approach is shown in scheme-1.



SCHEME – 1

Experimental:

Melting points were determined in open capillary tubes and were uncorrected. The IR spectra were recorded in KBr pellets on a Nicolet 400D spectrometer and ^{1}H NMR and ^{13}C NMR spectra were recorded in DMSO with TMS as internal standard on a Bruker spectrometer at 400 MHz and 100 MHz, respectively. LC-MS of selected samples taken on LC-MSD-Trap-SL_01046.

Preparation of 4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)-N-arylidene aniline:

***[2a-e]*:–** An equimolecular mixture of 4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl) aniline [1] (0.01mole) and the aromatic aldehydes [a-e] in ethanol (15ml) was refluxed on a water bath for 1-2.5 hrs. The solid separated was collected by filtration, dried and recrystallized from ethanol. The yields, melting points and other characterization data of these compounds are given in Table -1.

Preparation of 1-(4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)phenyl)-2-aryl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid [3a-e]:- A mixture of 4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)-N-arylidene aniline [2a-e] (0.01 mole) and Maleic anhydride (0.01mole) in chloroform (50ml) was refluxed for 5-7 hrs. The reaction mixture was allowed to stand for 2 days, the solid was filtered. The product thus formed was recrystallized from ethanol to give 1-(4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)phenyl)-2-aryl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid [3a-e], which were obtained in 62-78% yield. The yields, melting points and other characterization data of these compounds are given in Table -2.

Results and Discussion:

It was observed that 4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl)aniline [1] undergoes facile condensation with aromatic aldehydes to afford the corresponding 4-(1H-naphtho[1,8-de] [1,2,3]triazin-1-ylsulfonyl)-N-arylidene aniline [2a-e]. The structures of [2a-e] were confirmed by elemental analysis and IR spectra showing an absorption band at 1630-1660cm^{-1}(C=N), 3030-3085 cm^{-1} (C-H, of Ar.),1170-1150 cm^{-1} (SO_2),1340-1335 cm^{-1} (SO_2), 2815-2850cm^{-1} (CH_3).^{1}H NMR :7.30 – 8.20(10H, m, Ar-H),8.43-8.80 (1H, s, N=CH),2b; 2.1 (3H,s,CH_3) 2e; 3.90 (3H,s,OCH_3). ^{13}C NMR: 163.2-115.6 (Ar-22C), 160.3(-N=CH); (4b): 55.5-56.7 (-OCH_3). The C, H, N analysis data of all compounds are presented in Table -1.

The structures assigned to 1-(4-(1H-naphtho[1,8-de][1,2,3]triazin-1-ylsulfonyl) phenyl)-2-aryl-5-oxo-2,5-dihydro-1H-pyrrole-3-carboxylic acid [3a-e] were supported by the elemental analysis and IR spectra showing an absorption bands at 1720cm^{-1}(C=O of pyrrole ring), 3040-3058 cm^{-1}(C-H, of Ar.),3450-3550 cm^{-1}(-OH),1660-1670 cm^{-1} (-CO of -COOH), 1170-1150 cm^{-1} (SO_2), 1340 -1335 cm^{-1} (SO_2) for [3a] compound. ^{1}H NMR: 6.15-8.27 (15H, m,Ar-H), 4.72(1H,s, C_2H of the ring), 5.19(1H,s,C_4H),12.96(1H,s)(-COOH), 3b; 2.1 (3H, s, CH_3), 3e; 3.90 (3H,s,OCH_3). The C, H, N, S analysis data of all compounds are presented in Table-2.

The examination of elemental analytical data reveals that the elemental contents are consistence with the predicted structure shown in Scheme-1. The IR data also direct for assignment of the predicted structure. The final structure of all compounds is confirmed by LC-MS. LC-MS data of Samples 3b and 3e gives the molecular ion peak (m/z) at 539 and 568 respectively. These values are corresponds to their molecular weight.

Biological Screening:

Antibacterial activities

The antibacterial activities of all the compounds were studied against gram-positive bacteria (*Staphylococcus aureus and Bacillus subtilis*) and gram-negative bacteria (*E.coli, and klebsiella promioe*) at a concentration of 50µg/ML by agar cup plate method. A methanol system was used as control in this method. Similar conditions using tetracycline as a control was used standard for comparison. The area of inhibition of zone measured in cm. Compounds 3c and 3e were found more toxic for microbes. Other compounds found to be less or moderate active than tetracycline Tables -3.

Antifungal Activities

The fungicidal activity of all the compounds was studied at 1000 ppm concentration in vitro. Plant pathogenic organisms used were *Nigrospora Sp, Aspergillus niger, Botrydepladia thiobromine, and Rhizopus nigricum***,** *Fusarium oxyporium*. The antifungal activities of all the compounds [3a-e] were measured on each of these plant pathogenic strains on a potato dextrose agar (PDA) medium. Such a PDA medium contained potato 200g, dextrose 20g, agar 20g and water 1c. Five days old cultures were employed. The compounds to be tested were suspended (1000ppm) in a PDA medium and autoclaved at 120^{o} C for 15 min. at 15atm. pressure. These media were poured into sterile Petri plates and the organisms were inoculated after cooling the Petri plates. The percentage inhibition for fungi was calculated after five days using the formula given below:

Percentage of inhibition = 100(X-Y) / X

Where, X = Area of colony in control plate

Y = Area of colony in test plate

The fungicidal activity displayed by various compounds [3a-e] is shown in Tables-4.

Table:-1 Analytical Data and Elemental Analysis of Compounds [2a-e]

Compd.	Molecular formula (Mol. wt.)	LC-MS Data	Yield	M.P.* ^{0}C	Elemental Analysis							
					%C		% H		%N		%S	
					Found	Calcd.	Found	Calcd.	Found	Calcd.	Found	Calcd.
2a	$C_{23}H_{16}N_4O_2S$ (412)	438	86	248-249	66.95	66.97	3.88	3.91	13.56	13.58	7.75	7.77
2b	$C_{24}H_{18}N_4O_2S$ (426)	443	82	240-242	67.58	67.59	4.23	4.25	13.12	13.14	7.50	7.52
2c	$C_{23}H_{15}ClN_4O_2S$ (446)	457	84	242-244	61.80	61.81	3.36	3.38	12.52	12.54	7.15	7.17
2d	$C_{23}H_{15}BrN_4O_2S$ (490)	502	85	239-241	56.21	56.22	3.05	3.08	11.38	11.40	6.51	6.53
2e	$C_{24}H_{18}N_4O_3S$ (442)	459	87	242-243	65.12	65.14	4.07	4.10	12.65	12.66	7.23	7.25

***** Uncorrected

Table:-2 Analytical Data and Elemental Analysis of Compounds [3a-e]

Compd.	Molecular formula (Mol. wt.)	LC-MS Data	Yield	M.P.* ^{0}C	Elemental Analysis							
					%C		% H		%N		%S	
					Found	Calcd.	Found	Calcd.	Found	Calcd.	Found	Calcd.
3a	$C_{27}H_{18}N_4O_5S$ (510)	523	78	221-223	63.50	63.52	3.54	3.55	10.95	10.97	6.26	6.28
3b	$C_{28}H_{20}N_4O_5S$ (524)	539	76	218-220	64.09	64.11	3.82	3.84	10.67	10.68	6.10	6.11
3c	$C_{27}H_{17}ClN_4O_5S$ (544)	562	79	217-219	59.50	59.51	3.13	3.14	10.27	10.28	5.86	5.88
3d	$C_{26}H_{17}BrN_4O_5S$ (588)	595	75	219-221	55.00	55.02	2.90	2.91	9.50	9.51	5.42	5.44
3e	$C_{28}H_{20}N_4O_6S$ (540)	568	77	222-223	62.19	62.21	3.71	3.73	10.35	10.36	5.91	5.93

***** Uncorrected

Table:-3 Antibacterial Activity of Compounds [3a-e]

Compounds	Gram +Ve		Gram -Ve	
	Staphylococcus aureus	***Bacillus subtilis***	***E.coli***	***Klebsiella promioe***
3a	53	49	66	59
3b	52	54	63	72
3c	58	66	74	61
3d	50	55	62	54
3e	59	63	76	74
Tetracycline	60	68	80	77

Table:-4 Antifungal Activity of Compounds [3a-e]

	Zone of Inhibition at 1000 ppm (%)				
Compounds	***Botrydepladia Thiobromine***	***Rhizopus Nigricum***	***Aspergillus Niger***	***Nigrospora Sp.***	***Fusarium oxyporium***
3a	59	60	58	56	63
3b	57	57	56	60	60
3c	71	66	59	69	67
3d	63	58	57	58	61
3e	68	69	63	57	65

Acknowledgement:

The authors are thankful to -department Head, Department of Chemistry, for providing laboratory facilities.

"Cite this article"

Tarunkumar M. Patel * A.M Patel "Study of Novel Pyrrole Derivatives" Int. J. of Pharm. Res. & All. Sci.2012; Volume 1, Issue 4,27-30

References:

1. E. Gursoy, N. Guzeldemirci-Ulusoy, *Eur. J. Med. Chem.* **2007**, 42, 320.
2. R. Kalsi, M. Shrimali, T. N. Bhalla, J. P. Barthwal, *Indian J. Pharm. Sci.* **2006**, 41,353.
3. Y. Janin, *Bioorg. Med. Chem.* **2007**, 15, 2479.
4. M. R. Rao, K. Hart, N. Devanna and K. B. Chandrasekhar, *Asian J. Chem.* **2008**, 20,1402.
5. D. Sriram, P. Yogeeswari, K. Madhu, *Bioorg. Med. Chem. Lett.* **2006**, 15, 4502.
6. A. Nayyar and R. Jain, *Curr. Med. Chem.* **2006**, 12, 1873.
7. S.Rollas, N.Gulerman and H.Erdeniz, *Farmaco*, **2002**, 57, 171.
8. Terzioglu N., Gursoy A., *Eur. J. Med. Chem.*, **2003**, 38, 781.
9. S. Gemma, G. Kukreja, C. Fattorusso, M. Persico, M. Romano, M. Altarelli, L. Savini, G. Campiani, E. Fattorusso, N. Basilico, *Bioorg. Med. Chem. Lett.* **2006**, 16, 5384.
10. R. M. Fikry, N. A. Ismael, A. A El-Bahnasawy., A. A. Sayed El-Ahl, *Phosphorus Sulfur and Silicon.* **2006**, 179, 1227.
11. İ.Küçükgüzel, Ş.G.Küçükgüzel, S.Rollas, G.Ötük-Sanış, O.Özdemir, İ. Bayrak, T. Altuğ, J.P.Stables, *Il Farmaco*, **2004**,59,893-901.
12. S.Rollas, N.Kalyoncuoglu, D.Sur-Altiner, Y.Yegenoglu, *Pharmazie*, **1993**,48,308.
13. G.Turan-Zitouni, M.F.Sıvacı, S.Kılıç, K.Erol, *Molecules*, **2006**,11,477.
14. LQ Al- Mawsawi, R.Dayam, L.Taheri, M.Witvrouw, Z.Debyser, N.Neamati, *Bioorg. Med. Chem. Lett.* **2007**, 17(23), 6472.
15. C.Plasencia, R.Daym, Q.Wang, J.Pinski, T. R. Jr. Burke, D. I.Quinn and N. Neamati, *Mol. Cancer Ther.* **2005**, 4(7) 1105.
16. K.M.Thaker ,*Ind. J. Chem.*,**2003**,42B,1544.
17. V.S.Ingle, A.R.Sawale, R.D. Ingle and R.A. Mane,*Ind. J. Chem.*, **2000**,40, 124.
18. R.C. Sharma and D.Kumar , *J. Ind. Chem. Soc.*,**2000**,77, 492.
19. A.Bijev, *Lett.Drug Des. Discov.*, **2006**,3, 506.
20. H.Zhao, N.Neamati, S.Sunder, H.Hong, S.Wang, G. W.Milne, Y.Pommier, T. R. Jr. Burke, *J. Med. Chem.* **1997**, 40(6) 937.